The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-human phase 1 dose-escalation study of AV-203, a monoclonal antibody against ERBB3, in patients with metastatic or advanced solid tumors.
John Sarantopoulos
No relevant relationships to disclose
Michael S. Gordon
Consultant or Advisory Role - AVEO
Research Funding - AVEO
R Donald Harvey
No relevant relationships to disclose
Kamalesh Kumar Sankhala
No relevant relationships to disclose
Laeeq Malik
No relevant relationships to disclose
Devalingam Mahalingam
No relevant relationships to disclose
Taofeek Kunle Owonikoko
No relevant relationships to disclose
Colleen Margaret Lewis
No relevant relationships to disclose
Francis Payumo
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
Jim Miller
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
Christine Powell
Consultant or Advisory Role - AVEO
Other Remuneration - AVEO
Zhigang Weng
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
Philip B. Komarnitsky
Employment or Leadership Position - AVEO
Suresh S. Ramalingam
Consultant or Advisory Role - AVEO
Research Funding - AVEO